Comparing BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Evogene (NASDAQ:EVGN)

Evogene (NASDAQ:EVGN) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Evogene and BridgeBio Oncology Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1	0	0	1	2.50
BridgeBio Oncology Therapeutics	1	0	7	0	2.75

BridgeBio Oncology Therapeutics has a consensus price target of $24.80, suggesting a potential upside of 165.38%. Given BridgeBio Oncology Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Evogene.

Profitability

This table compares Evogene and BridgeBio Oncology Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evogene	-638.12%	-158.82%	-80.37%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

Volatility & Risk

Evogene has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

Insider and Institutional Ownership

10.4% of Evogene shares are owned by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Evogene and BridgeBio Oncology Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$1.84 million	2.96	-$8.48 million	($1.39)	-0.45
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04 million	($2.05)	-4.56

Evogene has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Summary

BridgeBio Oncology Therapeutics beats Evogene on 8 of the 14 factors compared between the two stocks.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

About BridgeBio Oncology Therapeutics

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.